Observational Multicenter Study of Relationship between Peripheral Neuropathy and Effectiveness in 2nd Line Therapy for Unresectable Advanced Gastric Cancer

Observational Multicenter Study of Relationship between Peripheral Neuropathy and Effectiveness in 2nd Line Therapy for Unresectable Advanced Gastric Cancer - IVY Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000033376

Enrollment

200

Registered

2018-09-15

Start date

2018-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)This is a case of unresectable or recurrent gastric cancer histologically confirmed to be the primary adenocarcinoma of the stomach. 2)Patient's age is over than 20 years old 3)Cases with Performance Status (PS) of 0-2 in ECOG 4)Patients who have been fully informed of this study and have given written informed consent 5)Patients resisted first line chemotherapy consisted of fluorinated pyrimidine anticancer drugs (e.g., 5-FU, S-1, capecitabine, UFT) and platinum anticancer drugs (cisplatin or oxaliplatin) for unresectable or recurrent gastric cancer.

Exclusion criteria

Exclusion criteria: 1)Patient's prognosis is within three months 2)With severe complications (angina pectoris, myocardial infarction and arrhythmia) and uncontrollable DM, blood hypertension and bleeding tendency 3)History of serious allergic reaction and with serious drug allergy 4)With clinically relevant mental disorder to be unable to answer questionnaires 5)Patients for whom the attending physician considered enrollment in the study inappropriate

Design outcomes

Primary

Measure	Time frame
relationship between frequency of peripheral neuropathy and effectiveness of chemotherapy	—

Countries

Japan

Contacts

Public ContactHiroaki Tanioka

Kawasaki Medical School Department of Clinical Oncology

tanioka@med.kawasaki-m.ac.jp0864621111

Outcome results